In a thematic debut, Jörn Schattenberg and Roger Green host interviews with three listeners from the Surfing NASH community to discuss four prominent questions around:
- the “straightjacket” of biopsy
- how we think about “tests” when not classed as “NITs” as compared to biopsy
- how do we all become better centered on patient needs
- the idea of combination therapy
In this second installment, Jerry Mabary joins Roger to discuss NASH-TAG 2023 and the future of Fatty Liver.
Jerry previously appeared on the podcast when he worked at Echosens and led their side of the LIVErHEALTHY launch. Now, he has joined Chronwell, a LIVErHEALTHY partner and GE practice management support firm. As befits his background, Jerry’s conversation reflects heavily on non-invasive testing as well as the role digital apps will play in patient treatment. He weaves all this into an integrated vision of Fatty Liver care that incorporates issues with the role of biopsy present and future. Finally, he notes ideas around the impact combination therapy will have on treatment over time.
Each guest in these fully-featured interviews shares on-ground experiences which collectively cast invaluable light on how the information featured in Surfing the NASH Tsunami is digested and applied in everyday life. As the podcast enters its fourth season, and embarks on affiliated journeys like the Rising Tide series, we hope to grow our community engagement. If you enjoy our content, we kindly ask that you submit a review wherever you download our episodes. We also encourage our audience to write us questions and look forward to integrating your on-ground experiences and perspectives in the weekly discourse.
Most important of all, we whole-heartedly thank you for your continued support as we set out to put a major dent in Fatty Liver disease in 2023 and beyond.
Stay safe and surf on!
